1. Home
  2. NCPL vs DRMA Comparison

NCPL vs DRMA Comparison

Compare NCPL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$1.15

Market Cap

9.2M

Sector

Finance

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.68

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
DRMA
Founded
1984
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
2.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NCPL
DRMA
Price
$1.15
$2.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
15.7M
102.5K
Earning Date
12-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$917,291.00
N/A
Revenue This Year
$739.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$2.34
52 Week High
$8.75
$23.70

Technical Indicators

Market Signals
Indicator
NCPL
DRMA
Relative Strength Index (RSI) 44.93 38.67
Support Level $0.97 $2.66
Resistance Level $1.94 $2.98
Average True Range (ATR) 0.31 0.29
MACD 0.05 0.03
Stochastic Oscillator 35.61 35.37

Price Performance

Historical Comparison
NCPL
DRMA

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: